# US 2021/0332102 A1 · High-affinity t cell receptor against prame

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332102 A1
- Document ID: US20210332102A1
- Status: Published application
- Kind: A1
- Application number: 17/254,432
- Filed: 2018-11-23
- Published: 2021-10-28
- Earliest claimed: 2017-12-06
- Assignees: Guangdong Xiangxue Life Sciences, Ltd.
- Applicants: Guangdong Xiangxue Life Sciences, Ltd.
- Inventors: Yi LI; Jinhua HUANG; Kai ZHAN
- Web page: https://patentgrep.com/patent/US20210332102A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 39/001189: {PRAME}
- A61P 35/00: Antineoplastic agents
- C07K 16/3053: {Skin, nerves, brain}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/5156: {expressing foreign proteins}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a T cell receptor (TCR) having a feature of binding to a VLDGLDVLL-HLA A2 complex. The binding affinity of the TCR to the VLDGLDVLL-HLA-A0201 complex is at least 2 times of the binding affinity of a wild-type TCR to the VLDGLDVLL-HLA-A0201 complex. Also provided is a fusion molecule of the TCR and a therapeutic agent. The TCR can be used alone or in combination with a therapeutic agent to target a tumor cell presenting the VLDGLDVLL-HLA-A0201 complex.

## Claims

### Claim at position 1

1-60. (canceled)

### Claim 61

A T cell receptor (TCR), which has an activity of binding to VLDGLDVLL-HLA-A0201 complex, the T cell receptor comprises a TCR α chain variable domain and a TCR β chain variable domain, the α chain variable domain of the TCR comprises an amino acid sequence having at least 90% of sequence homology with the amino acid sequence shown in SEQ ID NO: 1, and the β chain variable domain of the TCR comprises an amino acid sequence having at least 90% of sequence homology with the amino acid sequence shown in SEQ ID NO: 2, the TCRα chain variable domain comprises three CDR regions, and the reference sequences of the three CDR regions of the TCR α chain variable domain are listed as follows,
CDR1α:
DRGSQS
CDR2α:
IYSNGD
CDR3α:
AVARTYTGNQFY,
the TCR β chain variable domain comprises three CDR regions, and the reference sequences of the three CDR regions of the TCR β chain variable domain are listed as follows,
CDR1β:
SEHNR
CDR2β:
FQNEAQ
CDR3β:
ASSSQKFSGIQPQH,
and the TCRα chain variable domain contains at least one of the following mutations:
Residue before mutation
Residue after mutation
S at position 4 of CDR1α
T or A
S at position 6 of CDR1α
A
I at position 1 of CDR2α
Q or L or T
Y at position 2 of CDR2α
V
S at position 3 of CDR2α
M or V or Q
N at position 4 of CDR2α
P or D
A at position 3 of CDR3α
V
R at position 4 of CDR3α
L
T at position 5 of CDR3α
S
Y at position 6 of CDR3α
W
T at position 7 of CDR3α
K or A or R or L or Q or F
G at position 8 of CDR3α
S
N at position 9 of CDR3α
T
Q at position 10 of CDR3α
G or R
and/or, the TCR β chain variable domain contains at least one of the following mutations:
Residue before mutation
Residue after mutation
N at position 3 of CDR2β
D or G
E at position 4 of CDR2β
S or R
A at position 5 of CDR2β
I or S
Q at position 6 of CDR2β
E
S at position 3 of CDR3β
N
S at position 4 of CDR3β
A or P or N or K or Q or T or M or R
Q at position 5 of CDR3β
S or G or T
K at position 6 of CDR3β
P or G or L
F at position 7 of CDR3β
V or L.

### Claim 62 (depends on 61)

The TCR of claim 61, wherein the affinity of the TCR for VLDGLDVLL-HLA-A0201 complex is at least 2 times of that of the wild type TCR.

### Claim 63 (depends on 61)

The TCR of claim 61, wherein the TCR comprises a TCR α chain variable domain and a TCR β chain variable domain, the TCR α chain variable domain comprises CDR1α, CDR2α and CDR3α, and the sequence of CDR3α is selected from the group consisting of:
AVARTYTGNQFY, AVARSWKSNQFY, AVARSWASNQFY, AVARTYRSTGFY and AVARTYKSTGFY; and/or the amino acid sequence of CDR1α is selected from the group consisting of:
DRGSQS, DRGTQA, DRGAQA and DRGSQA; and/or the amino acid sequence of CDR2α is selected from the group consisting of:
IYSNGD, QVMPGD, QVVPGD and LVQPGD.

### Claim 64 (depends on 61)

The TCR of claim 61, wherein the TCR comprises a TCRα chain variable domain and a TCRβ chain variable domain, and the TCRβ chain comprises CDR1β, CDR2β and CDR3β, wherein the amino acid sequence of CDR1β is: SEHNR; and/or the amino acid sequence of CDR2β is selected from the group consisting of:
FQNEAQ, FQDSIE and FQGRSQ; and/or the amino acid sequence of CDR3β is selected from the group consisting of:
ASSSQKFSGIQPQH,
ASNSGPVSGIQPQH,
ASNQSGFSGIQPQH,
ASSMSGFSGIQPQH
and
ASSSGLLSGIQPQH.

### Claim 65 (depends on 61)

The TCR of claim 61, wherein the TCR has CDRs selected from the group consisting of:
TCR No.
CDR1α
CDR2α
CDR3α
CDR1β
CDR2β
CDR3β
1
DRGSQS
IYSNGD
AVARSWKSNQFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
2
DRGSQS
IYSNGD
AVARTYLSNRFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
3
DRGSQS
IYSNGD
AVARTWASNQFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
4
DRGSQS
IYSNGD
AVARSYQSNQFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
5
DRGSQS
IYSNGD
AVARSWFSNQFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
6
DRGSQS
IYSNGD
AVARTYKSNRFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
7
DRGSQS
IYSNGD
AVARTYKSNQFY
SEHNR
FQNEAQ
ASSSQKFSGIQPQH
8
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNSSGFSGIQPQH
9
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASSASGFSGIQPQH
10
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASSPSGFSGIQPQH
11
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNNSGFSGIQPQH
12
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNKSGFSGIQPQH
13
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNSGPVSGIQPQH
14
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNQSGFSGIQPQH
15
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASNTSGFSGIQPQH
16
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASSMSGFSGIQPQH
17
DRGSQS
IYSNGD
AVARTYTGNQFY
SEHNR
FQNEAQ
ASSSGLLSGIQPQH
18
DRGSQS
QVMPGD
AVARSYKSNQFY
SEHNR
FQDSIE
ASNSGPVSGIQPQH
19
DRGSQS
QVVPGD
AVARTYKSTGFY
SEHNR
FQGRSQ
ASNSGPVSGIQPQH
20
DRGTQA
QVMPGD
AVARTYKSNGFY
SEHNR
FQDSIE
ASNSSGFSGIQPQH
21
DRGSQS
QVMPGD
AVARSWASNQFY
SEHNR
FQDSIE
ASSMSGFSGIQPQH
22
DRGSQS
QVMPGD
AVARSWKSNQFY
SEHNR
FQDSIE
ASSRTGFSGIQPQH
23
DRGSQA
QVMPGD
AVARTYRSTGFY
SEHNR
FQDSIE
ASNSGPVSGIQPQH
24
DRGTQA
QVMPGD
AVARTYKSTGFY
SEHNR
FQDSIE
ASNSSGFSGIQPQH
25
DRGSQS
QVMPGD
AVARTWASNQFY
SEHNR
FQDSIE
ASNQSGFSGIQPQH
26
DRGTQA
LVQPGD
AVARTYKSTGFY
SEHNR
FQDSIE
ASNSGPVSGIQPQH
27
DRGSQA
QVVPGD
AVARTWASNQFY
SEHNR
FQDSIE
ASNSGPVSGIQPQH
28
DRGSQS
LVQPGD
AVARTYKSTGFY
SEHNR
FQGSAQ
ASNSGPVSGIQPQH
29
DRGAQA
QVMPGD
AVARSWASNQFY
SEHNR
FQDSIE
ASNQSGFSGIQPQH
30
DRGTQA
QVVPGD
AVARSWKSNQFY
SEHNR
FQDSIE
ASNQSGFSGIQPQH
31
DRGSQA
QVMPGD
AVARSWTSNQFY
SEHNR
FQDSIE
ASNQTGFSGIQPQH
32
DRGAQA
IYSNGD
AVARSYKSNQFY
SEHNR
FQDSIE
ASSRTGFSGIQPQH
33
DRGAQA
TVQDGD
AVARSWKSNQFY
SEHNR
FQDSIE
ASNQSGFSGIQPQH
34
DRGSQA
IYSNGD
AVARSWKSNQFY
SEHNR
FQDSIE
ASNSGPVSGIQPQH
35
DRGTQA
QVMPGD
AVVLSYKSNGFY
SEHNR
FQDSIE
ASNSSGFSGIQPQH
36
DRGAQA
QVMPGD
AVARSWKSNQFY
SEHNR
FQDSIE
ASSRTGFSGIQPQH

### Claim 66 (depends on 61)

The TCR of claim 61, wherein the TCR is soluble.

### Claim 67 (depends on 61)

The TCR of claim 61, wherein the TCR is an αβ heterodimeric TCR;
preferably, the TCR comprises (i) all or part of the TCR α chain other than its transmembrane domain, and (ii) all or part of the TCR β chain other than its transmembrane domain, wherein both of (i) and (ii) comprise the variable domain and at least a portion of the constant domain of the TCR chain;
more preferably, an artificial interchain disulfide bond is contained between the α chain constant region and the β chain constant region of the TCR;
most preferably, cysteine residues forming an artificial interchain disulfide bond between the TCR α chain constant region and β chain constant region are substituted for one or more groups of amino acids selected from the following:
Thr48 of TRAC*01 exon 1 and Ser57 of TRBC1*01 or TRBC2*01 exon 1;
Thr45 of TRAC*01 exon 1 and Ser77 of TRBC1*01 or TRBC2*01 exon 1;
Tyr10 of TRAC*01 exon 1 and Sen 7 of TRBC1*01 or TRBC2*01 exon 1;
Thr45 of TRAC*01 exon 1 and Asp59 of TRBC1*01 or TRBC2*01 exon 1;
Ser15 of TRAC*01 exon 1 and Glu15 of TRBC1*01 or TRBC2*01 exon 1;
Arg53 of TRAC*01 exon 1 and Ser54 of TRBC1*01 or TRBC2*01 exon 1;
Pro89 of TRAC*01 exon 1 and Ala19 of TRBC1*01 or TRBC2*01 exon 1; and
Tyr10 of TRAC*01 exon 1 and Glu20 of TRBC1*01 or TRBC2*01 exon 1.

### Claim 68 (depends on 61)

The TCR of claim 61, wherein the amino acid sequence of the α chain variable domain of the TCR is selected from the group consisting of: SEQ ID NOs: 57-82; and/or the amino acid sequence of the β chain variable domain of the TCR is selected from the group consisting of: SEQ ID NOs: and 83-100.

### Claim 69 (depends on 61)

The TCR of claim 61, wherein the TCR is selected from the group consisting of:
Sequence of α chain variable
Sequence of β chain variable
TCR No.
domain SEQ ID NO:
domain SEQ ID NO:
1
57
2
2
58
2
3
59
2
4
60
2
5
61
2
6
62
2
7
63
2
8
1
83
9
1
84
10
1
85
11
1
86
12
1
87
13
1
88
14
1
89
15
1
90
16
1
91
17
1
92
18
64
93
19
65
94
20
66
95
21
67
96
22
68
97
23
69
93
24
70
95
25
71
98
26
72
93
27
73
93
28
74
99
29
75
98
30
76
98
31
77
100
32
78
97
33
79
98
34
80
93
35
81
95
36
82
97.

### Claim 70 (depends on 61)

The TCR of claim 61, wherein the TCR is a single chain TCR;
preferably, the TCR is a single-chain TCR consisting of an α chain variable domain and a β chain variable domain, and the α chain variable domain and the β chain variable domain are connected by a flexible short peptide sequence (linker).

### Claim 71

A TCR, wherein the TCR is selected from the group consisting of:
Sequence of α chain variable
Sequence of β chain variable
TCR No.
domain SEQ ID NO:
domain SEQ ID NO:
s-1
9
4
s-2
10
4
s-3
11
4
s-4
12
4
s-5
13
4
s-6
14
4
s-7
15
4
s-8
3
35
s-9
3
36
s-10
3
37
s-11
3
38
s-12
3
39
s-13
3
40
s-14
3
41
s-15
3
42
s-16
3
43
s-17
3
44
s-18
16
45
s-19
17
46
s-20
18
47
s-21
19
48
s-22
20
49
s-23
21
45
s-24
22
47
s-25
23
50
s-26
24
45
s-27
25
45
s-28
26
51
s-29
27
50
s-30
28
50
s-31
29
52
s-32
30
49
s-33
31
50
s-34
32
45
s-35
33
47
s-36
34
49.

### Claim 72 (depends on 61)

The TCR of claim 61, wherein a conjugate binds to the α chain and/or β chain of the TCR at C- or N-terminal;
preferably, the conjugate that binds to the TCR is a detectable label, a therapeutic agent, a PK modified moiety, or a combination thereof;
more preferably, wherein the therapeutic agent that binds to the TCR is an anti-CD3 antibody linked to the α or β chain of the TCR at C- or N-terminal.

### Claim 73 (depends on 61)

A multivalent TCR complex, wherein the complex comprises at least two TCR molecules, and at least one TCR molecule is the TCR of claim 61.

### Claim 74 (depends on 61)

An isolated cell expressing the TCR of claim 61.

### Claim 75 (depends on 61)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier, and a TCR of claim 61, or a TCR complex, or a cell;
wherein the TCR complex comprises at least two TCR molecules, and at least one TCR molecule is the TCR of claim 61; and
the cell expresses the TCR of claim 61.

### Claim 76 (depends on 61)

A method for treating a disease, comprising administering an appropriate amount of the TCR of claim 61, or a TCR complex, or a cell, or a pharmaceutical composition to a subject in need thereof;
wherein the TCR complex comprises at least two TCR molecules, and at least one TCR molecule is the TCR of claim 61;
the cell expresses the TCR of claim 61; and
the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and a TCR of claim 61, or a TCR complex comprising at least two TCR molecules, and at least one TCR molecule is the TCR of claim 61, or a cell expressing the TCR of claim 61.

### Claim 77 (depends on 61)

A method for treating tumor, comprising administering an appropriate amount of the TCR of claim 61, or a TCR, or a cell to a subject in need thereof;
wherein the TCR complex comprises at least two TCR molecules, and at least one TCR molecule is the TCR of claim 61;
the cell expresses the TCR of claim 61.

### Claim 78 (depends on 61)

A method for preparing the T cell receptor of claim 61, comprising the steps of:
(i) culturing a host cell which can express the T cell receptor of claim 61 to express the T cell receptor;
(ii) isolating or purifying the T cell receptor.
